This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
After Golden Cross, Invesco (IVZ)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IVZNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
by Zacks Equity Research
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
SYKNegative Net Change ALGNPositive Net Change CAHNegative Net Change CORNegative Net Change
earnings medical medical-devices
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
by Indrajit Bandyopadhyay
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
CLOVNegative Net Change OSCRNegative Net Change ALHCPositive Net Change
medical medical-devices
Resmed Q4 Earnings & Revenues Beat Estimates, Stock Up, Margins Climb
by Zacks Equity Research
RMD tops Q4 earnings and revenue estimates with double-digit growth, rising margins and strong global device demand.
BSXNegative Net Change RMDPositive Net Change MEDPNegative Net Change WGSNegative Net Change
earnings medical medical-devices
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
BSXNegative Net Change WSTPositive Net Change GKOSPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
CONMED Q2 Earnings & Revenues Beat Estimates, 2025 Outlook Raised
by Zacks Equity Research
CNMD reports solid second-quarter results, driven by improving sales across both segments.
BSXNegative Net Change CNMDPositive Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
Merit Medical Q2 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
MMSI beats second-quarter 2025 earnings estimates as gross margin expands and strong U.S. and Cardiovascular sales drive revenue growth.
BSXNegative Net Change MMSINegative Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
by Zacks Equity Research
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
DVANegative Net Change EHCNegative Net Change ELANPositive Net Change AVAHNegative Net Change
earnings medical medical-devices
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
by Debanjana Dey
HIMS is transforming digital healthcare with AI-driven care, a booming subscriber base, and new tech leadership.
HIMSNegative Net Change LFMDPositive Net Change DOCSNegative Net Change
medical medical-devices
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
by Zacks Equity Research
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
BAXPositive Net Change ALGNPositive Net Change CAHNegative Net Change CORNegative Net Change
earnings medical medical-devices
Should You Buy Medpace (MEDP) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MEDPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
by Zacks Equity Research
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
ALGNPositive Net Change CAHNegative Net Change DXCMPositive Net Change CORNegative Net Change
earnings medical medical-devices
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
by Indrajit Bandyopadhyay
OPRX's subscription shift, DAAP platform, and HCP-DTC reach suggest a moat is forming-but is it built to last?
OPRXPositive Net Change VEEVNegative Net Change DOCSNegative Net Change
medical medical-devices
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
by Zacks Equity Research
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
BSXNegative Net Change HOLXNegative Net Change MEDPNegative Net Change WGSNegative Net Change
earnings medical medical-devices
Can Sustained Product Demand Drive HIMS Stock Before Q2 Earnings?
by Zacks Equity Research
Hims & Hers benefits from strong product demand and subscriber growth ahead of second-quarter 2025 earnings, fueled by weight loss and specialty care uptake.
OMCLPositive Net Change VEEVNegative Net Change INSPPositive Net Change HIMSNegative Net Change
earnings medical medical-devices
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
BSXNegative Net Change WSTPositive Net Change MEDPNegative Net Change GEHCNegative Net Change
earnings medical medical-devices
TEMENOS GROUP (TMSNY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TMSNYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TransAlta (TAC) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TACNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PRMEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regions Financial (RF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is the Options Market Predicting a Spike in InfuSystems Holdings Stock?
by Zacks Equity Research
Investors need to pay close attention to InfuSystems Holdings stock based on the movements in the options market lately.
INFUNegative Net Change
medical medical-devices
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
by Moumi Mondal
CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.
AGLPositive Net Change HUMNegative Net Change CVSNegative Net Change
medical medical-devices
Charles River Q2 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
CAHNegative Net Change CRLNegative Net Change CORNegative Net Change EXASNegative Net Change
earnings medical medical-devices
Ecolab Stock Down in Pre-Market Post Q2 Earnings Miss, Margins Expand
by Zacks Equity Research
ECL stock dips in pre-market despite second-quarter 2025 earnings growth and margin expansion, as EPS misses estimates by a penny.
BSXNegative Net Change ECLNegative Net Change WSTPositive Net Change MEDPNegative Net Change
earnings medical medical-devices
Should You Buy AppFolio (APPF) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
APPFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines